Albendazole 400 mg single dose vs mebendazole 500 mg single dose
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted5 studies · 1902 participantsLow
Findings
What do systematic reviews say?
53 questions · 54 findings · 24 reviews · Headline outcomes only
No studies found 6 · 11.1%GRADE not reported 4 · 7.4%Very low 22 · 40.7%Low 11 · 20.4%Moderate 10 · 18.5%High 1 · 1.9%
Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose
Adverse events · people with urinary schistosomiasis
1 finding from 1 review
- no estimate extracted8 studies · 992 participantsLow
Single‐dose, preoperative MMC‐EMDA vs single‐dose, postoperative MMC‐PD
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
- Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes onlyRR 0.79 [0.3, 2.05]1 study · 236 participantsVery low
Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy
Minor adverse events
1 finding from 1 review
- Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 72 participantsVery low
Albendazole 400 mg single dose vs albendazole 400 mg multiple doses
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted3 studies · 316 participantsModerate
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy
Adverse events during treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
- Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 131 participantsLow
Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy
Serious adverse events
1 finding from 1 review
- Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 311 participantsVery low
Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes onlyRR 0.41 [0.33, 0.5]5 studies · 3346 participantsLow
A single dose of deworming drugs vs placebo
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted4 studies · 744 participantsModerate
Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer
Adverse events · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
- Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 118 participantsVery low
Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care
Adverse events · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether single foetal haemoglobin inducer at any dose or duration changes adverse events compared with usual care or placebo (very low certainty).
1 finding from 1 review
- Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 56 participantsVery low
Single inhaler therapy vs fixed dose ICS
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 0.37 [0.05, 2.62]3 studies · 4209 participantsModerate
Single‐dose, preoperative MMC‐EMDA vs TURBT alone
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
- Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes onlyRR 1.74 [0.52, 5.77]1 study · 233 participantsVery low
Single inhaler therapy vs fixed dose ICS
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 0.97 [0.73, 1.29]3 studies · 4209 participantsModerate
Single inhaler therapy vs fixed dose ICS
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 0.57 [0.35, 0.93]2 studies · 2586 participantsHigh
160/4.5 mcg BDF single inhaler therapy vs current best practice
Fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 1.95 [0.53, 7.21]8 studies · 8841 participantsLow
Non‐platinum single‐agent vs non‐platinum combination treatment
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes onlyRR 1.184 studies · 983 participantsVery low
160/4.5 mcg BDF single inhaler therapy vs current best practice
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 1.2 [0.9, 1.6]8 studies · 8841 participantsLow
Non‐platinum single‐agent vs non‐platinum combination treatment
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes onlyRR 1.195 studies · 1064 participantsLow